Navigation Links
VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes
Date:6/8/2009

ted group was the result of more aggressive medication intervention, while concurrent anti-diabetic medications were reduced in patients treated with Qnexa to meet the same glycemic thresholds. The results of the DM-230 study had previously been released but the ADA podium presentation represents the first time the trial results have been shared with the scientific and medical community.

Qnexa was well-tolerated, with no drug-related serious adverse events. The most common drug-related adverse events reported over the 56 weeks for the treatment and placebo groups, respectively, were tingling, nausea, dry mouth, dizziness, insomnia and constipation. Patients were monitored for depression and suicidality using the PHQ-9 questionnaire, the FDA's preferred mental health assessment tool. Patients treated with Qnexa demonstrated greater improvements in PHQ-9 scores from baseline to the end of the study than the placebo group, providing further assurance that Qnexa treatment does not produce significant adverse mood changes or suicidality.

Despite a mean baseline HbA1c level of 8.7 percent, 53 percent of the subjects treated with Qnexa were able to achieve the ADA recommended goal of 7.0 percent or lower, versus 40 percent of the subjects in the placebo arm (p<0.05). The incidence of treatment-related hypoglycemia was similar in the treatment and placebo arms (2.7% and 1.8%, respectively). There were no cases of severe hypoglycemia.

About Diabetes

Diabetes, a chronic medical condition, affects more than 23 million people in the United States and nearly 250 million people worldwide. An estimated 17.9 million have been diagnosed with the disease, however, nearly one quarter are unaware that they have diabetes. New cases of diabetes doubled over the last ten years due to obesity and lifestyle and it is now calculated that the lifetime risk of diabetes in this century is approximately 35 per
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. New Diabetes Drug Shows Promise in Trial
2. Vaporized viral vector shows promise in anti-cancer gene therapy
3. New Survey Shows Americans Strongly Support Guaranteed Dental Coverage in Healthcare Reform
4. Global Testing Shows No Variation in Swine Flu Virus
5. New Study Shows Many U.S. Contact Lens Wearers Do Not Comply With Recommended Replacement Schedules
6. Protein may be strongest indicator of rare lung disease, study shows
7. People who wear rose-colored glasses see more, University of Toronto study shows
8. Computer modeling shows strategies to rein in epidemics need to be retooled for rural populations
9. New study shows people with mental health problems receive inadequate medical care
10. The Killing of George Tiller: Video "Thine Eyes" Shows True Face of Pro-life Movement in the Face of 'Terrorist' Accusations
11. New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder ... the first in the area to offer RADIESSE® filler treatment for volume loss in ... prominence of tendons and veins in the hands, delivering smooth, natural-looking results that can ...
(Date:9/1/2015)... , ... September 01, 2015 , ... A new episode ... Jones, will take a look at the topic of arthritis. There are over 100 ... will explore interesting arthritis types and statistics in an effort to shed light on ...
(Date:9/1/2015)... ... September 01, 2015 , ... Specialty Technical Publishers ... International Audit Protocol Consortium (IAPC) EHS audit protocol for the European Union. Leading ... of their EHS regulatory obligations and rapidly collect, share, archive, and export audit ...
(Date:8/31/2015)... ... September 01, 2015 , ... AthleticTraining.com, provider of CEUs for ... of new premium on-demand video Evidence Based Practice courses that ... 2014 must complete 50 CEUs before December 31, 2015, which must include at ...
(Date:8/31/2015)... ... August 31, 2015 , ... Jvion, the ... latest predictive use case focused on helping hospital perform under the Center for ... hospital payments are adjusted based on performance across four domains related to care ...
Breaking Medicine News(10 mins):Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2
... resonance imaging (MRI) to evaluate cardiovascular risk in World ... School of Medicine have found that the responders who ... cloud on September 11, 2001, demonstrate high-risk features of ... the American Heart Association,s Scientific Sessions 2011 in Orlando, ...
... A component of garlic oil may help release protective compounds ... as a treatment for heart failure. At low concentrations, ... from damage. However, this unstable and volatile compound has been ... University School of Medicine have turned to diallyl trisulfide, a ...
... (HealthDay News) -- One in five male breast cancer patients stops ... the medicine and may be at increased risk for cancer recurrence, ... the hormone treatment of male breast cancer patients, according to the ... of the Annals of Oncology . In the study, ...
... The largest study to investigate the tolerability of the breast ... that men stop taking their prescribed therapy early because of ... The authors of the research paper, published today in the ... records of 64 male breast cancer patients at their institution ...
... nation,s state police agencies reported that they equip their ... 60 percent of said only a minority of their ... new research from the Perelman School of Medicine at ... at the American Heart Association,s annual Scientific Sessions (Abstract ...
... have developed a new genetic screening tool that ... for patients with melanoma and the unique genetic ... data presented at the AACR-NCI-EORTC International Conference: Molecular ... Heinz-Herbert Fiebig, M.D., Ph.D., associate professor of ...
Cached Medicine News:Health News:WTC workers exposed earlier to dust cloud have higher risk of atherosclerotic lesions 2Health News:Garlic oil component may form treatment to protect heart 2Health News:Side Effects May Spur Men to Drop Tamoxifen for Breast Cancer 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 2Health News:Male breast cancer patients stop taking tamoxifen early because of drug-related side effects 3Health News:Panel of melanoma mutations opens door to new treatment possibilities 2
(Date:9/1/2015)... September 1, 2015 BerGenBio AS ... announces that it has appointed Hilde Furberg ... to its Board of Directors, effective immediately. ... experience in pharma and biotech and is currently Senior ... company. Previously her role was Vice President and General ...
(Date:9/1/2015)... September 1, 2015 Diabetes, ... 2015 market research report that charts the changing ... the added health concerns resulting from the metabolic ... factors: cardiovascular disease (CVD). Complete report ... spread across 270 pages, profiling 66 companies and ...
(Date:9/1/2015)... 1, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... that its affiliate has entered into a collaboration ... an exclusive license to develop and commercialize brodalumab. ... monoclonal antibody in development for patients with moderate-to-severe ... Valeant will hold the exclusive rights to develop ...
Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2015 Research Report 2Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2015 Research Report 3Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2015 Research Report 4Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4
... Md., April 26, 2012 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... providing health care services in China through the operations ... care hospitals and affiliated ambulatory clinics, today announced that ... first quarter of 2012 ended March 31, 2012 on ...
... 2012 Medical sales recruitment specialists Advance ... new global medical device survey for 2012-2013 suggesting a ... climate. The report, which was published this ... a highly detailed analysis drawn from ICD research,s panel ...
Cached Medicine Technology:Chindex International, Inc. to Report First Quarter 2012 Financial Results 2Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry 2
... use with the Moto Alpha unit, these new pads ... in which several successive runs may be sealed with ... to prevent a microplate from sticking to the block ... level of sealing performance, which means you can use ...
... Designed for use with the Moto Alpha unit, these ... cycle sequencing, in which several successive runs may be ... Alpha unit is engineered to prevent a microplate from ... pads provide an improved level of sealing performance, which ...
Microseal 'M' mats, seals 96-well plates, reusable, pkg of 10...
Omniseal TD mat. Reusable rubber mat for sealing PCR plates. 5 pk....
Medicine Products: